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Objectives.T os t u d y( 1 )t h ep r e v a l e n c eo fd i ﬀerent types of gestational trophoblastic neoplasia (GTN) in the local and nonlocal
populationofwomenatAlWaslHospital,atertiarylevelreferralcentrefornorthernEmirates,(2)thesafetyofcervicalpreparation
before uterine evacuation, (3) the role of repeat uterine evacuation in curing these cases, and (4) the percentage of cases ultimately
requiring chemotherapy. Material and Methods. Retrospective analysis of case records of 35 women with diagnosis of gestational
trophoblastic neoplasia were managed in the Department of Obstetrics and Gynecology at Al Wasl Hospital, over a 2-year period
between January 2007 to December 2008. Results. 35 cases of gestational trophoblastic neoplasia were seen in a 2-year period
(January 2007 to December 2008) at Al Wasl Hospital, with 7000 deliveries per year, prevalence being 1 in 400 live births. 60%
cases were local Arabs. Histopathology revealed complete mole in 13 cases, partial mole in 17 cases, hydropic degeneration of
villi in 4 cases, and no identiﬁable tissue in 1 case. No cases of choriocarcinoma or placental site trophoblastic tumour were seen
during the study period. 34% cases received cervical preparation with prostaglandins prior to surgical curettage. Complications
were minor. 62% were cured by primary suction curettage, 12% after second (repeat) uterine evacuation, and 25% needed single
drug chemotherapy. 8% cases defaulted after primary evacuation and were lost to followup. Conclusions. Prevalence of GTN in the
local Arab population is similar to other Asian populations. The majority of cases are cured by simple suction uterine curettage.
Cervical preparation with prostaglandins should be done in selected cases to avoid perforation during evacuation. Second (repeat)
uterine evacuation can be curative in some cases with strict selection criteria and avoid the need for chemotherapy. Regional
registry of cases is needed to estimate the true incidence of this disease.
1.Introduction
Gestational trophoblastic neoplasia is excessive and inap-
propriate proliferation of trophoblast after the pregnancy
has ended. It includes a spectrum of disease from the be-
nign hydatidiform mole (complete or partial mole), to the
malignant gestational trophoblastic tumour (invasive mole,
choriocarcinoma, and placental site trophoblastic tumour).
It is a rare but important pregnancy-related disorder with an
incidenceof1in400inAsiaandLatinAmerica.Themajority
of cases can be cured by simple surgical intervention. Those
cases requiring chemotherapy are generally cured with very
low toxicity regimen. Unlike other gynaecological malig-
nancies, fertility can be preserved and normal pregnancy
outcome anticipated [1]. The curability of this condition is
a milestone of success in the history of modern medicine.
However, the disease can recur, and referral to a specialist
centre is required to ensure proper monitoring and followup
of cases. We present a retrospective study of cases of GTN
over a 2-year period that were managed at our hospital,
which is a tertiary level teaching hospital.
2.MaterialandMethods
Gynaecological case records of 35 cases who were admitted
with the diagnosis of GTN during Jan. 2007 to Dec. 2008
were analysed and data recorded in a data collection tool
designed for the purpose of this study (Table 1). Data were
stored in Excel format and analysed, and descriptive statistics
were used. Cases were managed according to institutional
protocol based on RCOG (Royal College of Obstetricians2 ISRN Obstetrics and Gynecology
Table 1: Data collection tool: record form.
(a) Page-1
HC no: Age Parity Symptoms Signs Baseline USG ﬁndings Prev. preg Cx priming Suction evacuation
(Yrs.) Bleeding/vesicles LFD uterus/ov cysts B-HCG Mole/missed Yes/No Yes/No
(b) Page-2
Oxytocin Complication B-HCG F/U 2nd Evac Outcome F/U duration (months) Histopath Blood grp
Yes/No Reg/Irreg Yes/No Cured/need CT
and Gynaecologists) guidelines [2]. All cases admitted from
Accident & Emergency or Early Pregnancy Assessment Unit
at Al Wasl Hospital with suspected diagnosis of molar preg-
nancy had detailed pelvic ultrasound, chest X-ray, and Lab-
oratory investigations including full Blood count (FBC),
Blood group and Rh typing, and baseline serum β-HCG.
Suction curettage was done under general anaesthesia for all
cases by experienced staﬀ. One case presenting at 24-week
gestationwithpartialmolarchangesonultrasoundhadmed-
ical termination with Misoprostol (prostaglandin E1). Prior
cervical preparation with prostaglandins (PG E1 OR E2) was
done in selected cases with tightly closed cervical os and his-
tory of previous uterine surgery. Oxytocin injection was
given after evacuation if there was excessive haemorrhage.
Evacuated material was sent for histopathology by experi-
enced pathologists. These women were followedup in Gy-
necology Outpatients Clinic, by weekly serum β-HCG levels
till 3 values were negative, then monthly for 6 months, and
3 months for 1 year. If β-HCG levels showed rise or plateau
during followup, cases were readmitted for further ultra-
sound and managed as persistent trophoblastic disease. If ul-
trasound showed signiﬁcant retained tissue and β-HCG less
than 1500IU/L, re-evacuation under general anaesthesia was
done by senior level staﬀ. After histopathology report, fol-
lowup was continued with β-HCG, and the case was re-
ferred to Medical Oncology Department for chemotherapy
evaluation.Contraceptionwasadvisedfor1yeartillfollowup
completed.
3. Results
35 cases of GTN were seen in 2 years (January 2007 to
December 2008) with 7000 deliveries per year, giving a prev-
alence of 1 in 400 live births. On average, 1 to 3 cases were
encountered in a month. The Age of women in the study
ranged from 17 to 49 years. Maximum number of cases were
seen in 21 to 30 years age group. Parity ranged from 0 to 10,
and the majority were seen in the parity group 1 to 4.
Molar preg-3
16%
No prior
preg-6
16%
Miscarriage-5
13%
1 prev mole-2
55%
2 prev mole-1
Results (contd...)
Type of previous pregnancy
Full-term
delivery-21
Figure 1: Past obstetric history.
21 women (60%) were local Arab nationals, while 14
(40%) were expatriates. Amongst the expatriates, 7% were
European and remaining were Asians of diﬀerent nationali-
ties. The type of previous pregnancy in these cases is shown
in Figure 1. 51% of cases had no symptoms on presentation
and were diagnosed on early pregnancy scan. The remaining
presented withabdominal pain (6of 35—17%), bleeding per
vaginum (15 of 35—29%), and hyperemesis (1 of 35—3%).
Also 54% had no presenting signs. The remaining showed
Large for dates uterus (12 of 35—34%), Theca lutein ovarian
cysts (3 of 35—9%), and pre-eclampsia (1 of 35–3%).
The baseline β-HCG levels, ultrasound ﬁndings, and
blood group are shown in Figure 2. β-HCG level of more
than1lacunitsperlitrewasseeninthemajorityofcases,and
predominating blood group was “O” followed by “B”. Ultra-
sound showed clear picture of complete mole in 24 cases and
partial mole in 5 cases.
The type of cervical preparation used is shown in
Figure 3. 34% of cases had received prostaglandin prepa-
ration. Suction curettage was done in 34 cases (97%) and
medical termination using PGE1 (misoprostol) in 1 caseISRN Obstetrics and Gynecology 3
Baseline β-HCG
levels (IU/L)
Blood group Ultrasound ﬁndings
Not done
Total Total
4
13
15
1
35
O
A
B
AB
20
4
10
1
35
Complete mole
Partial mole
Missed miscarriage
?invasive mole
?molar changes
Scan not done
24
5
1
1
3
1
2-adm. from
outside for
re-evacuation
Baseline HCG levels, blood group type and initial USS ﬁndings:
Number of cases Number of cases Number of
cases
<1000
1000–10,000
10,000–100,000
>100,000
Figure 2: Initial investigations.
Cervical preparation
No priming-23
66%
20%
14%
Results (contd...)
PGE1-7
PGE2-5
Figure 3: Type of cervical preparation.
(3%) which presented at 24 weeks with severe pre-eclampsia
and partial mole. 14 of 34 cases received oxytocin infu-
sion after evacuation to control hemorrhage. Intraoperative
and immediate postoperative complications were minimal.
Cervical laceration was seen in 1 (3%), fever in 1 (3%),
hemorrhage in 2 (6%), and none in 31 cases (88%).
The histopathology type and number of each type need-
ing chemotherapy are shown in Figure 4.1 3w e r ec o m p l e t e
moles (6 needed chemotherapy), 17 were partial moles (1
needed chemotherapy), and 4 were hydropic degeneration of
villi. No cases of invasive mole, choriocarcinoma, or placen-
tal site trophoblastic tumour were seen in the study group.
Hence, 8 of 35 cases (22.8%) underwent chemotherapy. All
these cases received single-agent methotrexate regimen with
folinic acid as their FIGO risk score was low (0 to 6). Cervical
priming with prostaglandin was done in 1 out of these 8
cases which required chemotherapy. Second evacuation was
attempted in 7 out of these 8 cases.
30 cases (85.7%) had regular β-HCG followup, irregular
in 4 cases, and none in 1 case. 19 cases were followed up for
one year, 13 cases for less than 6 months, and three cases
defaulted. Probably some went to their country of origin for
followup. Figure 5 shows the outcome of management in our
institution. As seen in the ﬁgure, 20 cases (68%) were cured
0
5
10
15
20
25
30
35
7
6
13
16
1
17
4
0
4
1
0
1
Complete
mole-13
Partial
mole-17
Hydropic
degen of
villi-4
No tissue-1
Need CT
Numbers needing chemotherapy according to histopathology
No need for CT
Total no.
Figure 4: Histopathological subtypes
byﬁrstsuctioncurettageandfour(12%)bysecondcurettage.
8 cases (25%) needed chemotherapy.
4. Discussion
GTN is a rare disease with varied presentation, and clinicians
are still faced with many challenges in management. It in-
cludes both benign and malignant forms. The benign forms
have excellent prognosis with 100% cure rate after simple
surgical evacuation, and 5 to 8% need chemotherapy. Early
diagnosis by ultrasound, availability of sensitive β-HCG
assays, and introduction of eﬀective chemotherapy regimens
havemadethisoncefatalmalignancycurable.Whenpresent-
ing at early gestations, complete mole can be diﬀerentiated
from partial mole by histopathology of evacuated material4 ISRN Obstetrics and Gynecology
Cured by
suction
curettage alone
= 20 (57%)
Needed 2nd
evacuation
= 11 (31.4%)
Needed chemo
after 1st
evacuation = 1
Defaulted
= 3 (8.5%)
Needed chemo
= 7/11 (63.6%)
Cured
= 4/11 (36.3%)
Outcome of management
Total no. = 35
Figure 5: Management outcome.
and ploidy test. Immunostain with P57KIP2 conﬁrms com-
p l e t em o l e[ 2].
TheincidenceofGTNvariesfrom1in1000inthewestto
1 in 100 in Philippines. In our study, the prevalence was 1 in
400 live births. The actual incidence could not be calculated
as there is no national registry for this tumour. GTN is com-
mon at extremes of age, less than 15 years and more than 45
years [2]. The increased risk in these age groups is mainly for
complete molar pregnancy as the incidence of partial molar
pregnancy changes less across the age groups [2]. In our
s t u d y ,t h em a j o r i t yw a ss e e ni n2 1t o3 0y e a r sa g eg r o u p .I t
is known that molar pregnancy can recur [2], the recurrence
being 1 in 60 after 1 molar pregnancy, 1 in 10 after 2 molar
pregnancies, and 1 in 2 after 3 molar pregnancies. In our
study, 2 out of 35 cases had history of one previous molar
pregnancy, and 1 case had history of 2 previous molar preg-
nancies. The recurrence is usually of the same histopatholog-
ical type [3].
These cases usually present with bleeding per vaginum,
early pregnancy failure, hyperemesis, or excessive uterine en-
largement. Pre-eclampsia and hyperthyroidism are rare pres-
entations [4]. In our study, 50% cases had no signs or symp-
toms at presentation and were diagnosed by early pregnancy
scan.Nowadays,earlydiagnosisispossiblebyultrasoundand
Doppler [4]. In our study, 33 out of 35 cases were diagnosed
by pre-evacuation scan. Complete mole appears as anembry-
onic pregnancy and partial mole as cystic spaces in placenta
or transverse to anteroposterior sac diameter >1.5.
When cervical preparation is done using prostaglandin,
there is a theoretical risk of embolisation of trophoblastic
cells, and prolonged preparation should be avoided [4, 5]. A
case-controlled study of 219 patients [5] showed no evidence
that cervical ripening prior to evacuation was linked to high-
er risk for needing chemotherapy, but there was a link with
increasing uterine size and subsequent need for chemo-
therapy [5]. In our study, 1 out of the 8 cases who re-
ceived cervical preparation needed chemotherapy. We used
prostaglandin preparation for selected cases with tightly
closed os and history of previous uterine surgery.
Complications associated with GTN include hemor-
rhage, tumour embolisation, uterine perforation, and sepsis.
Thesewereminimal inourstudy. Uterineperforationduring
evacuation can be minimized if procedure is done by ex-
perienced personnel.
15% of complete moles and 0.5% of partial moles need
chemotherapy [2]. In our study, 6 out of 13 cases of com-
plete moles and 1 out of 17 cases of partial moles needed
chemotherapy. The true incidence cannot be calculated as all
molar pregnancies are not registered at one centre. The risk
of requiring chemotherapy is more when molar pregnancy
presents at an earlier gestation [6].
Repeatorseconduterineevacuationhasaroleinselected
cases of persistent gestational trophoblastic disease where β-
HCG is less than 1500IU/litre, and ultrasound shows sig-
niﬁcant retained molar tissue. Chemotherapy can be avoided
in these cases. Chemotherapy is more likely if there is his-
tological evidence of persistent gestational trophoblastic dis-
ease, and β-HCG is more than 1500IU/litre at the time of
repeat uterine evacuation. Third evacuation is no longer rec-
ommended [7]. In our study, 4 out of 11 cases who under-
went second evacuation were cured, while 7 cases ultimately
needed chemotherapy. This indicates the need for strict se-
lection criteria.
Followup of patients can be improved by adequate coun-
selling at the time of diagnosis. Nowadays, shortened dura-
tion of followup is advised for 6 months from the date of
evacuation if β-HCG becomes normal within 8 weeks of
evacuation. If β-HCG does not revert to normal within 8
weeks of evacuation, then followup is advised for 6 months
from the date of normalisation of the β-HCG. This reduces
anxiety for women and is cost eﬀective [4, 8, 9].
5. Conclusions
The prevalence of GTN among the Arab population appears
to be similar to other Asians, and there is need for establish-
ing a national registry to obtain the true incidence of the
disease. Appropriate diagnosis and treatment leads to nearISRN Obstetrics and Gynecology 5
100% cure. Majority of cases are cured by simple surgical
intervention (suction curettage). Cervical preparation is safe
in selected cases. Second evacuation should be reserved for
cases with strict selection criteria. Followup can be improved
by adequate counselling.
6. LearningPoints/Recommendations
(1) There should be a regional/national registry for GTN
where all these cases are registered and receive appro-
priate followup.
(2) All cases should have a baseline β-HCG level and
pelvic ultrasound before any intervention.
(3) Caution during uterine evacuation can avoid serious
complications.
(4) Cervical preparation with prostaglandin should be
done in selected cases, and prolonged preparation
should be avoided.
(5) Repeat evacuation in selected cases avoids need for
chemotherapy.
(6) All cases of persistent GTN should have FIGO risk
scoring and receive chemotherapy in specialised cen-
tres.
(7) Followup is ideal for one year, but cases should be
counselled for contraception and refrain from preg-
nancy for at least 6 months.
(8) Six weeks after the end of any subsequent pregnancy,
serum β-HCG sample should be evaluated, and pla-
centa should be sent for histopathology after any de-
livery.
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